X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
22
PharmaCompass offers a list of Montelukast Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Montelukast Sodium manufacturer or Montelukast Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Montelukast Sodium manufacturer or Montelukast Sodium supplier.
PharmaCompass also assists you with knowing the Montelukast Sodium API Price utilized in the formulation of products. Montelukast Sodium API Price is not always fixed or binding as the Montelukast Sodium Price is obtained through a variety of data sources. The Montelukast Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Montelukast manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Montelukast, including repackagers and relabelers. The FDA regulates Montelukast manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Montelukast API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Montelukast manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Montelukast supplier is an individual or a company that provides Montelukast active pharmaceutical ingredient (API) or Montelukast finished formulations upon request. The Montelukast suppliers may include Montelukast API manufacturers, exporters, distributors and traders.
click here to find a list of Montelukast suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Montelukast DMF (Drug Master File) is a document detailing the whole manufacturing process of Montelukast active pharmaceutical ingredient (API) in detail. Different forms of Montelukast DMFs exist exist since differing nations have different regulations, such as Montelukast USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Montelukast DMF submitted to regulatory agencies in the US is known as a USDMF. Montelukast USDMF includes data on Montelukast's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Montelukast USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Montelukast suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Montelukast Drug Master File in Japan (Montelukast JDMF) empowers Montelukast API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Montelukast JDMF during the approval evaluation for pharmaceutical products. At the time of Montelukast JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Montelukast suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Montelukast Drug Master File in Korea (Montelukast KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Montelukast. The MFDS reviews the Montelukast KDMF as part of the drug registration process and uses the information provided in the Montelukast KDMF to evaluate the safety and efficacy of the drug.
After submitting a Montelukast KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Montelukast API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Montelukast suppliers with KDMF on PharmaCompass.
A Montelukast CEP of the European Pharmacopoeia monograph is often referred to as a Montelukast Certificate of Suitability (COS). The purpose of a Montelukast CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Montelukast EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Montelukast to their clients by showing that a Montelukast CEP has been issued for it. The manufacturer submits a Montelukast CEP (COS) as part of the market authorization procedure, and it takes on the role of a Montelukast CEP holder for the record. Additionally, the data presented in the Montelukast CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Montelukast DMF.
A Montelukast CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Montelukast CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Montelukast suppliers with CEP (COS) on PharmaCompass.
A Montelukast written confirmation (Montelukast WC) is an official document issued by a regulatory agency to a Montelukast manufacturer, verifying that the manufacturing facility of a Montelukast active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Montelukast APIs or Montelukast finished pharmaceutical products to another nation, regulatory agencies frequently require a Montelukast WC (written confirmation) as part of the regulatory process.
click here to find a list of Montelukast suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Montelukast as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Montelukast API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Montelukast as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Montelukast and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Montelukast NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Montelukast suppliers with NDC on PharmaCompass.
Montelukast Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Montelukast GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Montelukast GMP manufacturer or Montelukast GMP API supplier for your needs.
A Montelukast CoA (Certificate of Analysis) is a formal document that attests to Montelukast's compliance with Montelukast specifications and serves as a tool for batch-level quality control.
Montelukast CoA mostly includes findings from lab analyses of a specific batch. For each Montelukast CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Montelukast may be tested according to a variety of international standards, such as European Pharmacopoeia (Montelukast EP), Montelukast JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Montelukast USP).
Market Place
